Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (Toxt) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in Calgb 50401 (Alliance)

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_78
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

The Comparison of De Novo Grade 3 Follicular Lymphoma and Transformed Grade 3 Follicular Lymphoma: Own Data

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2017English

Dichloroacetate-Induced Neuropathy in High Grade Follicular Lymphoma Patient

Acta Medica Medianae
2019English

Editorial “Joint Modeling of Longitudinal and Time-To-Event Data and Beyond”

Biometrical Journal
MedicineUncertaintyStatisticsProbability
2017English

Gene Expression Profiling Reveals a Close Relationship Between Follicular Lymphoma Grade 3A and 3B, but Distinct Profiles of Follicular Lymphoma Grade 1 and 2

Haematologica
Hematology
2018English

Recombinant Interferon-Α2b Added to Oral Cyclophosphamide Either as Induction or Maintenance in Treatment-Naive Follicular Lymphoma: Final Analysis of CALGB 8691

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2009English

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

Indian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

Efficacy and Safety of Obinutuzumab + Lenalidomide + Atezolizumab in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis of a Phase 1b/2 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

An Unusual Presentation of a Low Grade Follicular Lymphoma Masquerading as a Meningioma

Annals of Hematology & Oncology
2018English

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy